3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow Prostate Cancer Metastatic: new trials by email Literature Review of Prostate Cancer Metastatic trials Research Report on Prostate Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients Rosuvastatin 20mg, surgical castration - Prostate Cancer Metastatic | Phase 4 | Completed | National Cancer Institute, Egypt | 70 | 2019-01-15 | 2021-03-02 |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent cabazitaxel XRP6258, enzalutamide, abiraterone acetate - Prostate Cancer Metastatic | Phase 4 | Completed | Sanofi | 255 | 2015-11-09 | 2022-05-27 |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer CABAZITAXEL XRP6258, Prednisone, Prednisolone - Prostate Cancer Metastatic | Phase 4 | Completed | Sanofi | 10 | 2014-07-01 | 2016-06-02 |
Hypoalphalipoproteinemias (1) · Prostatic Neoplasms (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dyslipidemias (1) · Genetic Diseases, Inborn (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Hypolipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Neoplasms (1) · Neoplasms by Site (1) · Nutritional and Metabolic Diseases (1)
Prednisone (2) · Abiraterone Acetate (1) · Castration (1) · Prednisolone (1) · Rosuvastatin Calcium (1) · cabazitaxel (1) · enzalutamide (1)
Sanofi (2) · National Cancer Institute, Egypt (1)
Austria (1) · Belgium (1) · Czechia (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · Iceland (1) · India (1) · Ireland (1) · Italy (1) · Netherlands (1) · Norway (1) · Spain (1) · United Kingdom (1)
PMID 31566937, PMID 32926841, PMID 34274136, PMID 34450475, PMID 36480560, PMID 41186991, PMID 42020286
2014 (1)